Stage IV Cutaneous Melanoma AJCC v6 and v7 Active Not Recruiting Phase 3 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0091050 (Stage IV Cutaneous Melanoma AJCC v6 and v7)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02506153High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryTreatment
NCT01274338Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryTreatment